Bank of New York Mellon’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.28M | Sell |
93,430
-60
| -0.1% | -$822 | ﹤0.01% | 2974 |
|
|
2025
Q1 | $1.03M | Sell |
93,490
-507
| -0.5% | -$5.61K | ﹤0.01% | 3032 |
|
|
2024
Q4 | $1M | Buy |
93,997
+6,430
| +7% | +$68.5K | ﹤0.01% | 3147 |
|
|
2024
Q3 | $1.11M | Sell |
87,567
-9,052
| -9% | -$115K | ﹤0.01% | 3078 |
|
|
2024
Q2 | $1.62M | Buy |
96,619
+28,400
| +42% | +$477K | ﹤0.01% | 2913 |
|
|
2024
Q1 | $1.02M | Sell |
68,219
-1,885
| -3% | -$28.3K | ﹤0.01% | 3132 |
|
|
2023
Q4 | $1.05M | Buy |
70,104
+12,298
| +21% | +$184K | ﹤0.01% | 3157 |
|
|
2023
Q3 | $810K | Buy |
57,806
+11,886
| +26% | +$167K | ﹤0.01% | 3283 |
|
|
2023
Q2 | $475K | Buy |
+45,920
| New | +$475K | ﹤0.01% | 3619 |
|
|
2022
Q2 | – | Sell |
-67,486
| Closed | -$588K | – | 4699 |
|
|
2022
Q1 | $588K | Buy |
67,486
+7,197
| +12% | +$62.7K | ﹤0.01% | 3617 |
|
|
2021
Q4 | $573K | Sell |
60,289
-1,045
| -2% | -$9.93K | ﹤0.01% | 3715 |
|
|
2021
Q3 | $1.03M | Buy |
61,334
+5,277
| +9% | +$88.8K | ﹤0.01% | 3371 |
|
|
2021
Q2 | $856K | Buy |
56,057
+3,026
| +6% | +$46.2K | ﹤0.01% | 3509 |
|
|
2021
Q1 | $1.03M | Buy |
53,031
+1,145
| +2% | +$22.3K | ﹤0.01% | 3311 |
|
|
2020
Q4 | $935K | Sell |
51,886
-1,867
| -3% | -$33.6K | ﹤0.01% | 3283 |
|
|
2020
Q3 | $1.04M | Sell |
53,753
-1,560
| -3% | -$30.1K | ﹤0.01% | 3109 |
|
|
2020
Q2 | $1.44M | Buy |
55,313
+7,117
| +15% | +$186K | ﹤0.01% | 2881 |
|
|
2020
Q1 | $860K | Sell |
48,196
-39
| -0.1% | -$696 | ﹤0.01% | 3082 |
|
|
2019
Q4 | $1.61M | Buy |
48,235
+1,992
| +4% | +$66.5K | ﹤0.01% | 2953 |
|
|
2019
Q3 | $1.1M | Buy |
46,243
+1,795
| +4% | +$42.8K | ﹤0.01% | 3121 |
|
|
2019
Q2 | $1.6M | Buy |
+44,448
| New | +$1.6M | ﹤0.01% | 2930 |
|
|
2018
Q4 | – | Sell |
-8,923
| Closed | -$421K | – | 4281 |
|
|
2018
Q3 | $421K | Buy |
+8,923
| New | +$421K | ﹤0.01% | 3711 |
|